All posts by medical

Decline in Key Applications of Biochemistry Analysers During Covid-19 Crisis May Slow Growth Rate – Farmers Ledger

A recent market study on the global Biochemistry Analysers market reveals that the global Biochemistry Analysers market is expected to reach a value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% during the forecast period (2019-2029).

The Biochemistry Analysers market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global Biochemistry Analysers market. Further, the presented study offers accurate insights pertaining to the different segments of the global Biochemistry Analysers market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2620581&source=atm

The following doubts are addressed in the market report:

Key Highlights of the Biochemistry Analysers Market Report

The presented report segregates the Biochemistry Analysers market into different segments to ensure the readers gain a complete understanding of the different aspects of the Biochemistry Analysers market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2620581&source=atm

Segmentation of the Biochemistry Analysers market

Competitive Outlook

This section of the report throws light on the recent mergers, collaborations, partnerships, and research and development activities within the Biochemistry Analysers market on a global scale. Further, a detailed assessment of the pricing, marketing, and product development strategies adopted by leading market players is included in the Biochemistry Analysers market report.

The following manufacturers are covered:Thermo Fisher ScientificAbbottHORIBASiemens HealthcareXylem AnalyticsAgappe DiagnosticsRMSMicroLab InstrumentsLabindia Instruments

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeFully Automated Biochemistry AnalyserSemi Automated Biochemistry Analyser

Segment by ApplicationHospital and Diagnostic LaboratoriesHome CareAcademic and Research Institutes

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2620581&licType=S&source=atm

Link:
Decline in Key Applications of Biochemistry Analysers During Covid-19 Crisis May Slow Growth Rate - Farmers Ledger

Research On Global Biochemical Diagnostic Reagent Market (Impact Of COVID-19) Is Big Booming With Top Key Players Roche, Siemens Healthineers,…

Global Biochemical Diagnostic ReagentMarket 2020-2027

GlobalBiochemical Diagnostic Reagent Market Global Drivers, Restraints, Opportunities, Trends, and Forecasts up to 2027. Market Over viewing the present digitized world, 80% of the data generated is unstructured. Organizations are usingBiochemical Diagnostic Reagent technology to unravel the meaning of such data to leverage business strategies and opportunities. A myriad of unstructured data is available online in the form of audio content, visual content and social footprints.

The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2020-2027.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

The latestBiochemical Diagnostic Reagent market report published by Reports and Markets offers a competency-based analysis and global market estimate, developed using evaluable methods, to provide a clear view of current and expected growth patterns. The report also contains market analysis by geographic location across the globe as well as major markets.

Our new sample is updated which correspond in new report showing impact of COVID-19 on Industry

The key manufacturers covered in this report are @ Roche, Siemens Healthineers, Beckman Coulter, Randox, BioSino, Beijing Leadman Biochemistry, FosunPharma, Beijing Strong Biotechnologies, Dojindo Laboratories, Sysmex, and KAINOS Laboratories

For Better Understanding, Download Sample PDF Copy of Biochemical Diagnostic Reagent Market Research Report @

The report provides a calculated assessment of theBiochemical Diagnostic Reagent market data analyzed. It explains different opportunities for different industries, suppliers, organizations, and associations that offer different products and services, for example, by giving specific guidance on how to expand in the competition for reliable consumer services. The report provides detailed information on major market competitors and emerging companies with significant market share based on high-quality demand, revenue, sales, product manufacturers, and service providers.

Based on the demand and methods currently used by major market players, the market report provides detailed and succinct evaluations as well as predictions of structured future market growth rates. For better analysis, the report divides the market into different segments of the global market based on various parameters, including product or service quality, applications, and methods. The Biochemical Diagnostic Reagentmarket report provides comprehensive statistics on changes in product types, innovation, and progress that may be caused by inconsequential variations in the product profile. Trends such as mergers and acquisitions play a critical role in the business operation and expansion as every region holds its own exclusivity in terms of production conditions, potential consumers, geographic benefits for resource procurement, and others.

TheBiochemical Diagnostic Reagentmarket report contains comprehensive information on the most important factors that drive or slow the companys growth. The report contains an investigation into the evolution of competitive dynamics. It also provides specific information that helps you choose the right executions and steps for your business. It analytically presents information in the form of flowcharts, facts, diagrams, statistical graphs, and figures that show the status of relevant transactions on the global and regional levels.

The report offers in-depth assessment of the growth and other aspects of the Biochemical Diagnostic Reagentmarket in important countries (regions), including:

North America

Europe

Asia Pacific Counter

Middle East & Africa

Latin America

America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Reasons to Buy this Report

Gain detailed insights on theBiochemical Diagnostic Reagent industry trends

Find complete analysis on the market status

Identify theBiochemical Diagnostic Reagent market Counteropportunities and growth segments

Analyze competitive dynamics by evaluating business segments & product portfolios

Facilitate strategy planning and industry dynamics to enhance decision making

Research Methodology

The data that has been collected is from a multitude of different services that include both primary and secondary sources. The data also includes a list of the different factors that affect the Biochemical Diagnostic Reagent market either positively or negatively. The data has been subjected to a SWOT analysis that can be used to accurately predict the various parameters that are used to measure a companys growth. The strengths along with various weaknesses faced by a company are included in the report along with a comprehensive analysis of the different threats and opportunities that can be exploited.

Overview

The report published on the globalBiochemical Diagnostic Reagentmarket is a comprehensive analysis of a variety of factors that are prevalent in the Biochemical Diagnostic Reagentmarket. An industrial overview of the global market is provided along with the market growth hoped to be achieved with the products that are sold. Major companies who occupy a large market share and the different products sold by them in the global market are identified and are mentioned in the report. The current market share occupied by the globalBiochemical Diagnostic Reagentmarket from the year 2019to the year 2025 has been presented.

Get Complete TOCon this Premium Report, Click Here @

TABLE OF CONTENT

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2027

14 Analysts Viewpoints/Conclusions

15 Appendix

About Author:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Us:

Sanjay Jain

Manager Partner Relations & International

https://www.reportsandmarkets.com/

Ph: +1-352-353-0818 (US)

Go here to read the rest:
Research On Global Biochemical Diagnostic Reagent Market (Impact Of COVID-19) Is Big Booming With Top Key Players Roche, Siemens Healthineers,...

We Thought We Had COVID-19 In January, But What Do Our Antibodies Say? – KPBS

You probably know someone who thinks they had COVID-19 back in January. I happen to know someone like that pretty well.

My husband Seth was really sick in mid-January. I recently asked him what he remembered.

"It came on very suddenly, I woke up one morning, started getting ready for work, never made it to work," he said. "I was coughing so long and to such a degree that I had to force myself to stop coughing to gasp for breath."

He also had the chills so bad that he was sleeping in multiple layers of clothes under several blankets. Though he never took his temperature, despite strong suggestions from his wife.

After three weeks of this, I finally convinced him to go to urgent care. He got an inhaler and some antibiotics.

Then, about a month later, the coronavirus showed up in the U.S. It didnt take long for Seth to connect the dots.

"I would kind of wonder if this sudden, unusual illness could be attributed to that disease," he said.

I thought it was a possibility because Seth's symptoms so closely matched the COVID-19 symptoms. And a week after he got sick, I was knocked out for two days with complete exhaustion and body aches.

Of course, I wanted it to be true if we really had already survived coronavirus, while we'd still be cautious, it would feel like a huge worry had been lifted for ourselves and our almost 3-year-old son.

Then I heard about this study happening at the La Jolla Institute for Immunology. Researchers there are searching the world for antibodies from people whove survived COVID-19. The institute usually just runs antibody tests on people who had already tested positive for COVID-19, but they agreed to test Seth and me for this story.

RELATED: La Jolla Institute Leading Global Hunt For Antibodies To Coronavirus

When we showed up a nurse took blood samples from both of us, put them in a centrifuge and passed them off to Dr. Jen Dan, an infectious disease researcher. She began what's called an ELISA, a way of testing the blood samples to see whether they contained specific antibodies.

Dan would compare our blood to other samples from both people whove survived COVID-19 and people who hadn't been infected. If we had the same antibodies as the survivors, then we also very likely had the disease.

The test would take 24 hours to complete, so we'd have to wait another day to know whether our suspicions were founded.

Right now, antibody tests are pretty easy to find. You can buy them over the counter or on the internet, and many blood banks have started to offer them for free. But epidemiologists are heaping lots of caution on both the tests and their results. Some arent approved by the U.S. Food and Drug Administration and they can be wrong, even giving false positives.

Plus, even if you had antibodies, you don't know for sure whether you're immune, said Dr. Erica Ollmann Saphire, the director of a global antibody consortium at La Jolla Institute for Immunology.

"We think that most people that have been infected will have made an antibody response, but there may have been some that didn't," she said. "What we most need to know is whether the antibody response is protective, whether having those antibodies will mean that you won't get sick again."

The evidence suggests people with antibodies likely have immunity, but they don't know how much or how long it lasts, Saphire said. The research she's leading is working to find the very best antibodies from COVID-survivors, which will be used to treat COVID and hopefully prevent it in the first place.

With those best-of-the-best antibodies, Saphire hopes to make drugs that can treat COVID and help people from catching it in the first place.

The next day, Seth and I came back to the institute and watched Dan, the infectious disease researcher, finish the test. During the last step, she added a colorless solution to reveal the presence of antibodies. If there were antibodies, the mixture would turn blue.

The top two rows on her plate had the samples from the known coronavirus survivors, and those little wells of liquid quickly turned blue. Underneath those were Seth and my samples. I kept peering over them, hoping for two blues.

Dan had a great poker face, and not just because she was wearing a mask. She took the samples away to analyze them on her computer.

After what seemed to us like a long time, she came back and went over the results with Dr. Shane Crotty, an infectious disease expert at the institute. Crotty pulled up them on his computer. Suddenly, he seemed like a doctor who was very good at giving bad news.

"These are the positives," he said, pointing at several dots on a graph. "Today, here are the negatives that she ran, and here's Seth and here's Claire."

Our marks sat on the graph below all the other negatives. We were super negative. Meaning we definitely had not had COVID-19.

"We're below negative, not even negative," I said with a laugh.

"Yeah, you are," Crotty said.

But, our results make sense, he said.

"This certainly fits with the timeline in California, that there weren't any confirmed cases in California at the time you were sick," he said. "And even right now when people get (antibody) tests, you can see the numbers that are reported are 10% positive, which means nine out of 10 people who thought they were infected are frequently turning out that, no it wasn't."

So, the upshot from our little adventure is that despite what your friend, your neighbor or your husband might be telling you and what you might be telling yourself its highly unlikely that anyone in San Diego had COVID-19 before February.

KPBS' daily news podcast covering local politics, education, health, environment, the border and more. New episodes are ready weekday mornings so you can listen on your morning commute.

Claire Trageser Investigative Reporter

As a member of the KPBS investigative team, my job is to hold the powerful in San Diego County accountable. I've done in-depth investigations on political campaigns, police officer misconduct and neighborhood quality of life issues.

To view PDF documents, Download Acrobat Reader.

Go here to read the rest:
We Thought We Had COVID-19 In January, But What Do Our Antibodies Say? - KPBS

The 3 Best Coronavirus Stocks to Buy for Long-Term Investors – The Motley Fool

Let's face it: Some companies that are receiving a lot of hype right now about their COVID-19 programs won't have staying power. Small biotechs claiming to have a game-changing treatment on the way could run into the harsh realities of clinical testing. Diagnostic test makers with all of their chips on COVID-19 could be left in the dust a couple of years from now when the pandemic has run its course.

The stocks of such companies might be OK for traders to buy to make a quick buck in the short run. But they're unsuitable for investors seeking to generate big gains over the long run. Here are my picks for the three best coronavirus-related stocks to buy for long-term investors.

Image source: Getty Images.

Abbott Labs (NYSE:ABT) quickly rolled out several COVID-19 diagnostic tests after the coronavirus hit with full force earlier this year. Its ID NOW test, which received FDA Emergency Use Authorization (EUA) in late March, attracted significant attention because it offered the fastest results of any COVID-19 test available.

I expect that COVID-19 testing will continue to fuel sales growth for Abbott over the next few years. However, there are several more important growth drivers for the company.

Put Freestyle Libre at the top of the list. Abbott recently won FDA clearance for a new version of the continuous glucose monitoring (CGM) system that supports integration with other medical devices. My prediction is that Freestyle Libre 2 will enjoy skyrocketing consumer demand and be a resounding success for Abbott.

Wall Street analysts project that Abbott will be able to deliver average annual earnings growth of more than 10% over the next five years. I think that estimate is realistic. Throw in Abbott's reliable dividend, and you've got a blue chip stock with a COVID-19 focus that's likely to beat the total returns of the S&P 500 over the long run.

Gilead Sciences (NASDAQ:GILD) has been at the center of the coronavirus world since its antiviral drug remdesevir was first touted as a potential treatment for COVID-19. With late-stage clinical studies now supporting the safety and efficacy for remdesivir, Gilead is well positioned to remain a fixture in the fight against the novel coronavirus.

However, it's Gilead's treatment for another virus -- HIV -- that has been and will continue to be its biggest opportunity. The biotech's lineup includes multiple blockbuster HIV drugs. Gilead is evaluating a long-acting HIV therapy in phase 2 clinical studies that could be its greatest commercial success yet. Looking further down the road, the company could even have a cure for HIV on the way.

Thanks to its strategic partnership with Galapagos, Gilead is poised to make its mark in immunology. The company awaits U.S. and European regulatory approvals for filgotinib in treating rheumatoid arthritis. It also is likely to become an even bigger player in the oncology market with new indications for CAR-T therapy Yescarta potentially on the way and the acquisition earlier this year of cancer-focused biotech Forty Seven.

My view is that Gilead's COVID-19, HIV, immunology, and oncology programs will enable the big biotech to deliver solid growth over the long run. That growth will be bolstered by one of the most attractive dividends in the healthcare sector: Gilead's dividend yield currently stands at nearly 3.7%.

While lots of small biotechs have scrambled to develop COVID-19 therapies, I've kept my eyes onEli Lilly (NYSE:LLY). The big drugmaker has moved at breakneck speed with its partners to advance two COVID-19 antibody therapies into clinical studies. It's also evaluating blockbuster rheumatoid arthritis drug Olumiant and pipeline candidate LY3127804 in treating COVID-19.

I won't be surprised if Lilly achieves success with at least one of its coronavirus efforts. In the meantime, the company's diabetes drug franchise continues to rock along thanks primarily to strong sales for Jardiance and Trulicity. Lilly is also a top contender in the immunology market with Olumiant and Taltz.

The company's greatest growth opportunity, though, could be in oncology. Lilly recently announced overwhelmingly positive results from a late-stage study of Verzenio in treating early-stage breast cancer. It won FDA approval in May for Retevmo in treating lung and thyroid cancer. Cyramza also continues to pick up momentum in treating several solid tumors.

Analysts think that Lilly could deliver average annual earnings growth of nearly 13% over the next five years. That level seems quite attainable to me, considering the company's solid current lineup and promising pipeline. With Lilly's dividend yield of 1.8% included, I think the pharma stock should easily outperform the overall market's total returns over the long run.

Read more:
The 3 Best Coronavirus Stocks to Buy for Long-Term Investors - The Motley Fool

High-resolution proteins being built to fight COVID-19 – MSUToday

During the COVID-19 pandemic, MSU researchers are rising to the occasion and spearheading projects that seek to aid the international efforts to develop treatments for the virus. One such researcher is Michael Feig who is part of the Department of Biochemistry and Molecular Biology at MSU. He and his postdoc Lim Heo generated high accuracy models for the SARS-CoV-2 virus.

Seeing as these structural models were not available previously from experiment, these high accuracy models can now be used in further studies that test how certain chemicals respond to the proteins. These models are used as a starting point by other researchers for screening existing drugs or developing new drugs for their potential usage in treating COVID-19.

To read the full story and view a video with Feig, go to ICER.

Follow this link:
High-resolution proteins being built to fight COVID-19 - MSUToday

Bench-Top Veterinary Biochemistry Analyzers Market study with COVID-19 Impact Research, Major Players, Analysis, Industry Demand by Segmentation and…

The Bench-Top Veterinary Biochemistry Analyzers Market report market intelligence study intended to offer complete understanding of global market scenario with the Impact of COVID-19 (Corona Virus). It attempts to analyze the major components of the Market which have greater influence on it. This includes various elements of significant nature including market overview, segmentation, competition landscape, Market chain analysis, key players strategyand more. Also, the report provides a 360-degree overview of global market on the basis of various analysis techniques including SWOT and Porters Five Forces. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. This might help readers to understand the strengths, opportunities, challenges and perceived threats of the market.

The following Companies are coveredin theResearch Report:Idexx LaboratoriesURIT Medical ElectronicAbaxisLITEONHeskaBPC BioSedRandox LaboratoriesDiaSys Diagnostic SystemsScil Animal CareFuji FilmAMS AllianceiCubioCarolina Liquid ChemistriesCrony Instruments

Based on Classification, each type is studied as Sales, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. The report can help to realize the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Bench-Top Veterinary Biochemistry Analyzers industry.

The Bench-Top Veterinary Biochemistry Analyzers Market report wraps:

There are 13 Chapters to thoroughly display the Bench-Top Veterinary Biochemistry Analyzers market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

In the end, The objective of the market research report is the current status of the market and in accordance classifies it into a few objects. The report takes into consideration the first market players in every area from over the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Originally posted here:
Bench-Top Veterinary Biochemistry Analyzers Market study with COVID-19 Impact Research, Major Players, Analysis, Industry Demand by Segmentation and...

Alpacas helping UK researchers to combat COVID-19 – LEX18 Lexington KY News

LEXINGTON, Ky. (LEX 18) A team at the University of Kentucky College of Medicine is researching a possible treatment for COVID-19 and key helpers are three alpacas; Big Boy, Blue Eyes and Emperor.

Its a powerful technology that we have a UK and its something that hopefully we can develop some therapeutics with, said Wally Whiteheart, a professor in the Department of Molecular & Cellular Biochemistry.

Alpacas, along with llamas and camels, make a special kind of antibody called a nanobody. Nanobodies can be useful in cancer research and for other diseases. Researchers, led by Whiteheart and fellow professor Lou Hersh, are working with River Hill Ranch near Richmond to see what impact alpacas could have on COVID-19.

We in a sense vaccinate them, and this case with viral proteins, and we make nanobodies to those viral proteins, said Whiteheart. We can then go and purify and identify the nanobodies that bind to the virus and then test them to see if they can inhibit viral infection.

Making the nanobodies is just the first step. The team will see which, if any, can block virus infection and those candidates could move on to clinical trials.

Theres still a lot of research and testing to go, but also still a lot of hope.

The cool thing which were exploring now is the fact that you might be able to use them as a nasal spray and this actually gets them to the place where the virus is affecting lung tissue, said Whiteheart.

This isnt the first time the trio of alpacas has helped UK. Big Boy, Blue Eyes and Emperor have contributed to the universitys nanobody research for more than three years. In those years, they have helped researchers generate more than 50 nanobodies to target proteins involved in a variety of human diseases including cancer, diabetes and neurological disorders.

Read more:
Alpacas helping UK researchers to combat COVID-19 - LEX18 Lexington KY News

Richmond Alpacas Participating In Research To Prevent COVID-19 Infection – WKMS

Alpacas from a farm near Richmond are playing a key role in work to help prevent coronavirus in humans. Three Alpacas, Big Boy, Blue Eyes, and Emperor are all part of the camelid family which produces a small, unique anti-body.

University of Kentucky Molecular and Cellular Biochemistry Professor Wally Whiteheart says the nanobodies found in the Alpacas are small enough to access small areas of the coronavirus spike proteins. The idea is you can make these as inhibitors that block function and they block the ability of the virus to get inside a cell or even bind to a cell.

If more research and federal approval proves successful, Whiteheart envisions the ultimate protection to be found through an inhaler. The alpacas have participated in UKs nanobody research for more than three years.

UK's Wally Whitehouse offers this full explanation of the COVID-19 related research with Richmond area alpacas:

View original post here:
Richmond Alpacas Participating In Research To Prevent COVID-19 Infection - WKMS

Sugar-Coating Disguise Allows for Coronavirus Infection – UC San Diego Health

According to Mary Poppins, a spoonful of sugar helps the medicine go down. In the case of coronavirus, a cloak of sugar helps the virus infect. This sugary-coating disguise, made of molecules called glycans, tricks the human immune system into identifying the microbe as harmless. The resulting recognition failure keeps the body from generating the defensive antibodies needed to destroy the invading coronavirus.

Rommie Amaro, professor of chemistry and biochemistry, UC San Diego

Using the National Science Foundation-funded Frontera supercomputer at the Texas Advanced Computing Center (TACC), Professor ofChemistry and BiochemistryRommie Amaroalong with her UC San Diego colleagues and researchers from Maynooth University in Dublin, Ireland, led by Elisa Faddahas uncovered the atomic makeup of the coronavirus's sugary cloak. The simulation and modeling reveal that glycans also prime the coronavirus for infection by changing the shape of its spike protein. Scientists hope this basic research will add to the arsenal of knowledge needed to defeat the COVID-19 virus.

The more we know about it, the more of its abilities that we're going to be able to go after and potentially take out, Amaro said. It isof such great importance that we learn as much as we can about the virus. And then hopefully we can translate those understandings into things that will be useful either in the clinic or the streets; for example, if we're trying to reduce transmission for what we know now about aerosols and wearing masks. All these things will be part of it. Basic research has a huge role to play in the war against COVID-19. And I'm happy to be a part of it. It's a strength that we have Frontera and TACC in our arsenal.

Glycans coat each of the 65-odd spike proteins that adorn the coronavirus. The sugar-like molecules account for about 40 percent of the spike protein by weight. The spike proteins are critical to cell infection because they lock onto the cell surface, giving the virus entry into the cell.

Amaro, along with her UC San Diego colleagues Lorenzo Casalino, Zied Gaieb, Abigail Dommer, Emilia Barros and Bryn Taylor, explained that even to make an initial connection, one of the pieces of the spike protein in its receptor binding domain has to lift up. It is one of the things Fronterapart of the COVID-19 HPC Consortium along with San Diego Supercomputer Center at UC San Diegohelped reveal: that in the open conformation, there are two glycans that basically prop up the spike protein.

That was really surprising to see. It's one of the major results of our study. It suggests that the role of glycans in this case is going beyond shielding to potentially having these chemical groups actually being involved in the dynamics of the spike protein, said Amaro, a corresponding author of the study published online June 12, 2020, by bioRxiv,org, a preprint repository.

Glycan shield in SARS-CoV-2 spike. (A) Molecular representation of the Open. Glycans at several frames (every 20 ns) are represented with blue lines, and the receptor binding domain within chain A is highlighted with a cyan transparent surface. (B-C) Plot of the surface area covered by glycan shielding at multiple probe radii from 1.4 (water molecule) to 15 for the head (B) and stalk (C). The area of the protein covered by the glycans is depicted in blue, while the grey line is the accessible area of the protein without glycans. Highlighted in green is the area that remains accessible in the presence of glycans, which is also graphically depicted on the structure in the panels located above the plots. Credit: Lorenzo Casalino (UC San Diego), et al.

When that receptor binding domain lifts up into the open conformation, it actually lifts the important bits of the protein up over the glycan shield, Amaro said, adding that this contrasts with the closed conformation, where the shield covers the spike protein. Our analysis gives a potential reason why it does have to undergo these conformational changes, because if it just stays in the down position those glycans are basically going to block the binding from actually happening, she said, adding that the shifts in the conformations of the glycans triggered changes in the spike protein structure.

Amaro compared the action of the glycan to pulling the trigger of a gun. When that bit of the spike goes up, the finger is on the trigger of the infection machinery. That's when it's in its most dangerous modeit is locked and loaded, Amaro said. When it gets like that, all it has to do is come up against an ACE2 receptor in the human cell, and then it's going to bind super tightly and the cell is basically infected.

The research team used computational methods to build data-centric models of the SARS-CoV-2 virus, and then used computer simulations to explore different scientific questions about the virus. They started with various experimental datasets that revealed the structure of the virus. This included cryo-EM structures from the Jason McLellan Lab of The University of Texas at Austin; and from the lab of David Veesler at the University of Washington.

Their structures are really amazing because they give researchers a picture of what these important molecular machines actually look like, Amaro said.

SARS-CoV-2 virus spike protein system overview. (A) Sequence of the full-length spike protein contains the N-terminal domain (NTD), the receptor binding domain (RBD), the furin cleavage site, the fusion peptide (FP), the central helix (CH), the connecting domain (CD), the heptad repeat 2 (HR2) domain, the transmembrane domain (TD) and the cytoplasmic tail (CT). (B) Assembly of head, stalk, and cytoplasmic tail (CT) sections into a full-length model of the spike protein (C) Equilibrated, fully glycosylated and palmitoylated model of the Open system. (C-E) Magnified view of the N-/O- glycans (C, D) and S-palmitoylation of the cytoplasmic tail (E). Image by Lorenzo Casalino, et al.

Unfortunately, even the most powerful microscopes on Earth still can't resolve movement of the protein at the atomic scale.

What we do with computers is that we take the beautiful and wonderful and important data that they give us, but then we use methods to build in missing bits of information, Amaro said.What people really want to knowfor example, vaccineand drug developersare the vulnerabilities that are present in this shield.

The computer simulations allowed Amaro and colleagues to create a cohesive picture of the spike protein that includes the glycans.

The reason why the computer resources at TACC are so important is that we can't understand what these glycans look like if we don't use simulation, Amaro said.

In order to animate the dynamics of the 1.7 million atom system under study, a lot of computing power was needed, said Amaro.

That's really where Frontera has been fantastic, because we need to sample relatively long dynamics, microsecond to millisecond timescales, to understand how this protein is actually working. We've been able to do that with Frontera and the COVID-19 HPC Consortium, Amaro said. Now we're trying to share our data with as many people as we can, because people want a dynamical understanding of what's happeningnot only with other academic groups, but also with different pharmaceutical and biotech companies that are conducting neutralizing antibody development, she said, adding that basic research is making a difference in winning the war against the SARS-Co-V-2 virus.

This research was supported by NIH (GM132826), NSF (RAPID MCB-2032054), an award from the RCSA Research Corp., a UC San Diego Moore's Cancer Center 2020 SARS-COV-2 seed grant, the Visible Molecular Cell Consortium and the Irish Research Council.

See the article here:
Sugar-Coating Disguise Allows for Coronavirus Infection - UC San Diego Health

Academic’s ‘bold’ vision to save Sheffield ‘wildlife haven’ is backed by community – Yorkshire Live

An expert in biochemistry has detailed an alternative idea for how a Sheffield wildlife haven could be protected, and his "vision" for the area has been backed by a local community action group.

Councillors recently refused to allow Avant Homes to build 200 new homes on Owlthorpe Fields, land earmarked for housing for around 30 years which has since flourished with greenery and wildlife.

Dr Patrick Harrison, who was born and brought up in Waterthorpe, and is a lecturer in biochemistry at Hull University, spoke against the scheme at the planning meeting and has outlined an alternative idea.

He says the land would be better used as part of a two-mile wildlife corridor, starting at Owlthorpe Fields to the newly created wetland corridor that runs from Woodhouse Washlands to Holbrook.

It would connect the Westfield plantation, the Waterthorpe Park area which is currently being developed and Waterthorpe Meadows and Beighton ponds.

Dr Harrison said: "The premise of the corridor is born out of ideas developed for the creation of Waterthorpe Park where ecology, health and education are linked to create a space where the local community can use for their physical and mental wellbeing whilst being a giant outdoor classroom for local schools to underpin learning at all levels of the curriculum.

"It will require ambitious collaboration between various stakeholders such as Sheffield and Rotherham Wildlife Trust, community groups, schools, numerous council departments along with our universities but many of these connections are already in place.

"It now requires political will from Sheffield Council to accept the new realities of the world and the longer term benefits of such a scheme in terms of social care costs, education and biodiversity gain.

This is even more pressing in a post Covid-19 world where working arrangements will change so more people will be working and exercising in their local community.

Owlthorpe Fields Action Group, which had been set up in 2018 to oppose the Avant Homes development, have described the area as a "wildlife haven" and are backing Dr Harrison's vision for a wildlife corridor.

They have described it as "bold" and believe that it acknowledges the challenges posed by climate change, while encouraging community integration.

They said: "Its become crystal clear during the lockdown, just how important it is for residents to have access to a usable green open space on our doorsteps, for exercise, to maintain health, and perhaps even more importantly, for our peace of mind and wellbeing.

"We agree with the Council people must live somewhere, but the same goes for the animals, trees and plants living in Owlthorpe Fields. This land is not just a green field site. Its rewilded over decades, its rich in biodiversity, from the tiniest insect to buzzards flying overhead."

Owlthorpe Fields Action Group have since planned a "bio-blitz" for Saturday (June 20) where people can join them in a nature survey of the fields, which will be used to show the council how biodiverse the area is.

Members of the group will be at Owlthorpe Medical Centre at 10am, 12pm or 2pm on Saturday to meet and greet anyone who would like to take part, while adhering to social distancing regulations.

Read this article:
Academic's 'bold' vision to save Sheffield 'wildlife haven' is backed by community - Yorkshire Live